Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PI4KA | P42356 | 1/20 | 0.46 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.46 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.46 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.40 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31194479 | 1.00 | PI4KA (0.46) | PI4KAPI4K2BPI4K2API4KBSMN1; SMN2 | |
| SCHEMBL12370932 | 0.75 | PIK3CD (0.43) | PI4KBKDM4EKMT2AEGFR | |
| SCHEMBL31162924 | 0.75 | NPC1 (0.41) | SMN1; SMN2KDM4EALOX15ALDH1A1CYP1A2 | |
| SCHEMBL9983135 | 0.75 | NPC1 (0.41) | SMN1; SMN2KDM4EALOX15ALDH1A1CYP1A2 | |
| SCHEMBL2273854 | 0.74 | EGFR (0.34) | EGFR | |
| SCHEMBL31041708 | 0.74 | EGFR (0.34) | CYP1A2TSHREGFRUSP2 | |
| SCHEMBL887885 | 0.74 | EGFR (0.34) | EGFR | |
| SCHEMBL1128424 | 0.74 | EGFR (0.34) | CYP1A2TSHREGFRUSP2 | |
| SCHEMBL22317948 | 0.74 | EGFR (0.34) | ALDH1A1CYP1A2CYP3A4EGFRCYP2C9 | |
| SCHEMBL2244617 | 0.74 | XDH (0.46) | MEN1KMT2AALDH1A1CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-02-13 | — | — | US | claimed |
| EP-2718295-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | Pfizer Inc (US) | 2014-04-16 | — | — | EP | claimed |
| WO-2012168817-A1 | PYRAZOLO[3,4-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS PDE2 INHIBITORS AND/OR CYP3A4 INHIBITORS | PFIZER INC. (US) | 2012-12-13 | — | — | WO | claimed |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2011-08-18 | — | — | US | claimed |
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | AUGUSTINE THERAPEUTICS (BE) | 2025-09-23 | — | — | US | disclosed |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | PLIANT THERAPEUTICS, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2025-07-10 | — | — | US | disclosed |
| CN-120091811-A | Integrin inhibitors and their use in combination with other agents | 普利安特治疗公司 | 2025-06-03 | — | — | CN | disclosed |
| EP-4551204-A2 | INTEGRIN INHIBITORS AND USES THEREOF IN COMBINATION WITH OTHER AGENTS | Pliant Therapeutics, Inc. (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | AUGUSTINE THERAPEUTICS (BE) | 2025-05-08 | — | — | US | disclosed |
| EP-4520329-A2 | TREATMENT OF RESPIRATORY DISEASES WITH AMINO ACID COMPOUNDS | Pliant Therapeutics, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-2210881-A1 | Derivatives of syringolin A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2010-07-28 | — | — | EP | disclosed |
| WO-2010081731-A2 | DERIVATIVES OF SYRINGOLIN A | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V (DE) | 2010-07-22 | — | — | WO | disclosed |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | WYETH (US) | 2010-01-21 | — | — | US | disclosed |
| US-7589068-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-09-15 | — | — | US | disclosed |
| US-7579355-B2 | Inhibitors of Akt activity | MERCK & CO., INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20080107628-A1 | Polymerase inhibitors | GILEAD SCIENCES, INC. | 2008-05-08 | — | — | US | disclosed |
| US-20080009507-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-01-10 | — | — | US | disclosed |
| US-20070043001-A1 | Inhibitors of akt activity | MERCK SHARP & DOHME CORP. | 2007-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051319-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885 |
| US-20080107628-A1 | Polymerase inhibitors | POLR2H, POLR2E, POLR1E | PI4KA 754/4885PI4K2B 1398/4885PI4K2A 1595/4885 |
| US-20110201628-A1 | HETEROCYCLIC JAK KINASE INHIBITORS | JAK2, JAK1, JAK3 | PI4KA 279/4885PI4K2B 441/4885PI4K2A 481/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | PI4KA 1537/4885PI4K2B 1874/4885PI4K2A 1993/4885 |
| US-12390463-B2 | Dosage forms and regimens for amino acid compounds | ITGB6, ITGA6, ITGAV | PI4KA 2364/4885PI4K2B 2929/4885PI4K2A 2891/4885 |
| US-20070043001-A1 | Inhibitors of akt activity | MTMR1, PIK3CA, PLK1 | PI4KA 76/4885PI4K2B 123/4885PI4K2A 152/4885 |
| US-20250145604-A1 | COMPOUNDS AND USE THEREOF AS HDAC6 INHIBITORS | HDAC6, HDAC9, HDAC1 | PI4KA 3244/4885PI4K2B 2025/4885PI4K2A 2553/4885 |
| US-20250223288-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA6, ITGA5 | PI4KA 1052/4885PI4K2B 1572/4885PI4K2A 1661/4885 |
| US-20100015141-A1 | 4-PHENOXY-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDINE AND N-ARYL-6-ARYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES | MTOR, PIK3CA, PIK3CD | PI4KA 5/4885PI4K2B 20/4885PI4K2A 22/4885 |
| US-12421222-B2 | Substituted quinazolines as HDAC6 inhibitors | HDAC6, HDAC9, HDAC1 | PI4KA 3041/4885PI4K2B 2012/4885PI4K2A 2257/4885 |
| US-20080009507-A1 | Inhibitors of Akt Activity | PIK3CD, PIK3CA, PIK3CG | PI4KA 28/4885PI4K2B 47/4885PI4K2A 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.